Apollo Endosurgery to Report Third Quarter Financial Results on November 1, 2021
Apollo Endosurgery, Inc. (NASDAQ:APEN) will release its third quarter financial results on November 1, 2021, post-market. A live webcast audio call is scheduled for 3:30 p.m. CT to discuss these results. Investors can access the call via Apollo's website or dial in using +1-973-528-0011. Apollo focuses on minimally invasive medical devices aimed at gastrointestinal and bariatric procedures, offering products in over 75 countries.
- Scheduled release of Q3 financial results indicates potential for investor engagement.
- Apollo offers next-generation medical devices, enhancing market position in gastrointestinal care.
- None.
AUSTIN, TX / ACCESSWIRE / October 27, 2021 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2021 on Monday, November 1, 2021 after the market closes.
In conjunction with the release, Apollo will host a live webcast audio call with slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.
An audio-only option is available by dialing +1-973-528-0011 and referencing "Apollo Endosurgery Third Quarter 2021 Earnings Call" or PIN code 285478. Investors who opt for audio-only will need to download the related slides at www.apolloendo.com.
A replay of the webcast will be made available on Apollo's website, www.apolloendo.com, shortly after completion of the call.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on development of next-generation, less invasive devices to advance therapeutic endoscopy designed to treat a variety of gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack® Endoscopic HeliX Tacking System, the OverStitch® Endoscopic Suturing System, the OverStitch Sx® Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Apollo's common stock is traded on NASDAQ Global Market under the symbol "APEN". For more information on Apollo Endosurgery visit www.apolloendo.com.
Disclosure Information
Apollo uses the investor relations section of its website as a means of complying with its disclosure obligations under Regulation FD. Accordingly, we recommend that investors should monitor Apollo's investor relations website in addition to following Apollo's press releases, SEC filings, and public conference calls and webcasts.
CONTACT
Apollo Endosurgery, Inc.
Jeff Black, 512-279-5126
investor-relations@apolloendo.com
Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com
SOURCE: Apollo Endosurgery, Inc.
View source version on accesswire.com:
https://www.accesswire.com/669825/Apollo-Endosurgery-to-Report-Third-Quarter-Financial-Results-on-November-1-2021
FAQ
What date will Apollo Endosurgery release its Q3 2021 financial results?
What time is the Apollo Endosurgery Q3 2021 earnings call scheduled?
How can I access the Apollo Endosurgery earnings call?
What is the main focus of Apollo Endosurgery's products?
